Alterations in Genes of the EGFR Signaling Pathway and Their Relationship to EGFR Tyrosine Kinase Inhibitor Sensitivity in Lung Cancer Cell Lines
2009 · PLoS ONE · 204 citations
https://doi.org/10.1371/journal.pone.0004576
W
William W. Lockwood
BC Cancer Agency(CA)
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
377
Papers
7.5K
Citations
48
h-index
95
i10-index
William W. Lockwood is an academic researcher from BC Cancer Agency. The author has contributed to research in topics: Lung Cancer Treatments and Mutations & RNA modifications and cancer & Cancer Genomics and Diagnostics. The author has an h-index of 48, co-authored 321 publications.
ORCID: 0000-0001-9831-3408Papers by this author
worksEvidence that synthetic lethality underlies the mutual exclusivity of oncogenic KRAS and EGFR mutations in lung adenocarcinoma
2015 · eLife · 198 citations
https://doi.org/10.7554/elife.06907
SMARCA4 loss is synthetic lethal with CDK4/6 inhibition in non-small cell lung cancer
2019 · Nature Communications · 182 citations
https://doi.org/10.1038/s41467-019-08380-1
The Economic Development of Japan. Growth and Structural Change, 1868-1938.
1955 · Pacific Affairs · 128 citations
https://doi.org/10.2307/3035381
Hyperactivation of ERK by multiple mechanisms is toxic to RTK-RAS mutation-driven lung adenocarcinoma cells
2018 · eLife · 110 citations
https://doi.org/10.7554/elife.33718
Epithelial tumor suppressor ELF3 is a lineage-specific amplified oncogene in lung adenocarcinoma
2019 · Nature Communications · 70 citations
https://doi.org/10.1038/s41467-019-13295-y
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat